Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BetterLife PharmaBETRF -1.55%16 3-Year EBITDA Growth Rate is 56.20% as of Apr. 2026, which is 36% above its 10-year median of 41.30. GuruFocus rates BETRF with a GF Score™ of 16/100. The stock has 1 warning sign investors should review. Among 1,130 Biotechnology companies, BetterLife Pharma ranks better than 88.76% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 56.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 59.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BetterLife Pharma was 73.10% per year. The lowest was -100.10% per year. And the median was 41.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
BetterLife Pharma 3-Year EBITDA Growth Rate Related Terms
BETRF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, BetterLife Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BetterLife Pharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BetterLife Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where BetterLife Pharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 56.20% mean?
BetterLife Pharma (BETRF) has a 3-Year EBITDA Growth Rate of 56.20% as of Apr. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BetterLife Pharma and its competitors. This is 36% above median its historical median of 41.30. According to the industry distribution chart, BetterLife Pharma ranks #127 out of 1130 companies in the Biotechnology industry, placing it in the top 11.2%.
Is BetterLife Pharma's 3-Year EBITDA Growth Rate too high?
BetterLife Pharma's current 3-Year EBITDA Growth Rate of 56.20% is 36% above median its 10-year median of 41.30. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. BetterLife Pharma's value of 56.20% is 278.5% above this industry median. Based on the distribution chart, BetterLife Pharma ranks #127 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BetterLife Pharma has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does BetterLife Pharma's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BetterLife Pharma ranks #127 out of 1130 companies for 3-Year EBITDA Growth Rate. This places BetterLife Pharma in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. BetterLife Pharma's value of 56.20% is 278.5% above this benchmark. While the company's 10-year median is 41.30 vs. the industry median of 14.85, BetterLife Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BetterLife Pharma's current 3-Year EBITDA Growth Rate of 56.20% is 278.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BetterLife Pharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BetterLife Pharma's current 3-Year EBITDA Growth Rate is 56.20%, which is 36% above median its own 10-year median of 41.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BetterLife Pharma stock overvalued right now?
BetterLife Pharma (BETRF) has a current 3-Year EBITDA Growth Rate of 56.20%. The current 3-Year EBITDA Growth Rate is 56.20%, which is 36% above median its 10-year median of 41.30 and 278.5% above the Biotechnology industry median of 14.85. BetterLife Pharma's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For BetterLife Pharma (BETRF), the current 3-Year EBITDA Growth Rate is 56.20% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BetterLife Pharma Inc is a biopharmaceutical company engaged in the development of patented pharmaceuticals. It is an emerging biotechnology company mainly focused on developing compounds for the treatment of mental disorders. It is also refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight viral infections. The Company operates in one industry segment, development and commercialization of patented pharmaceuticals within one geographical area.
16GF Score
Get the complete analysis for BETRF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BETRF has been successfully added to your 
